{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:08:34Z","timestamp":1790820514113,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.semnuclmed.2025.11.013","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:38:07Z","timestamp":1765197487000},"page":"188-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of non-FDG agents in PET imaging of bladder cancer"],"prefix":"10.1053","volume":"56","author":[{"given":"Alireza","family":"Safarian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6243-3370","authenticated-orcid":false,"given":"Dina","family":"Muin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"H\u00f6rmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Dragonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-3812","authenticated-orcid":false,"given":"Mohsen","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-220106","article-title":"Recent advances in the classification of bladder cancer - updates from the 5th edition of the world health organization classification of the urinary and male genital tumors","volume":"9","author":"Guo","year":"2023","journal-title":"Bladder Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0002","article-title":"Advances in bladder preservation therapy for muscle-invasive bladder cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.013_bib0003","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cancers13061396","article-title":"Imaging and management of bladder cancer","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.013_bib0004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clgc.2022.01.009","article-title":"Impact of (18) FDG- PET CT in the management of muscle invasive bladder cancer","volume":"20","author":"Bertolaso","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort(\u2020): under the auspices of the EAU-ESMO guidelines committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0006","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1148\/radiol.2019190032","article-title":"Delayed (18)F FDG PET\/CT imaging in the assessment of residual tumors after transurethral resection of bladder cancer","volume":"293","author":"Yan","year":"2019","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.916693","article-title":"ImmunoPET: antibody-based PET imaging in solid tumors","volume":"9","author":"Manafi-Farid","year":"2022","journal-title":"Front Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.013_bib0008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3174\/ajnr.A2601","article-title":"Panitumumab (vectibix)","volume":"32","author":"Gemmete","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0009","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.humpath.2011.11.016","article-title":"High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues","volume":"43","author":"Chaux","year":"2012","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.013_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11307-022-01708-2","article-title":"EGFR-targeted ImmunoPET of UMUC3 orthotopic bladder tumors","volume":"24","author":"Hoang","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41181-021-00140-1","article-title":"Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab')(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab')(2) - implications for a PET theranostic strategy","volume":"6","author":"Ku","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0012","doi-asserted-by":"crossref","unstructured":"Sarrami, N., M. Wuest, I.M.d. Paiva, et al., Immuno-PET Imaging of EGFR with 64Cu-NOTA panitumumab in subcutaneous and metastatic non-small cell lung cancer xenografts. 2024. 21(11): p. 5797\u20135806.","DOI":"10.1021\/acs.molpharmaceut.4c00823"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.013_bib0013","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2967\/jnumed.119.236430","article-title":"PET\/CT imaging with an (18)F-labeled galactodendritic unit in a galectin-1-overexpressing orthotopic bladder cancer model","volume":"61","author":"Pereira","year":"2020","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0014","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","article-title":"Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma","volume":"48","author":"Merkx","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0015","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.013_bib0016","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/cancers17071190","article-title":"Preclinical and clinical feasibility studies as the first step before forthcoming intravesical instillation of [(211)At]At-anti-CA-IX antibody (ATO-101\u2122) study in patients with non-muscle-invasive bladder cancer unresponsive to standard of care","volume":"17","author":"Rousseau","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060478","article-title":"(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma","volume":"12","author":"Al-Zubaidi","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.013_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0b013e3283373d5c","article-title":"Image and treat': an individualized approach to urological tumors","volume":"22","author":"Bouchelouche","year":"2010","journal-title":"Curr Opin Oncol"},{"issue":"20","key":"10.1053\/j.semnuclmed.2025.11.013_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012659","article-title":"Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates","volume":"23","author":"Albarr\u00e1n","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.013_bib0020","first-page":"1018","article-title":"Quantitative [(89)Zr]Zr-trastuzumab PET and diffusion- weighted MRI for characterization of metastatic HER2-positive breast cancer with PET\/MRI","volume":"66","author":"Mansur","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13550-020-0603-9","article-title":"Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer","volume":"10","author":"Alhuseinalkhudhur","year":"2020","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.013_bib0022","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/biomedicines12051088","article-title":"Affibody PET imaging of HER2-expressing cancers as a key to guide HER2-targeted therapy","volume":"12","author":"Eissler","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-022-00738-6","article-title":"Recent advances in cancer imaging with (64)CuCl(2) PET\/CT","volume":"56","author":"Peng","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0024","first-page":"10596","article-title":"Imaging urothelial bladder cancer: a VPAC PET targeted approach","volume":"28","author":"Thakur","year":"2021","journal-title":"Can J Urol"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0025","doi-asserted-by":"crossref","first-page":"12s","DOI":"10.2967\/jnumed.123.266830","article-title":"Translational PET imaging of Nectin-4 expression in multiple different cancers with (68)Ga-N188","volume":"65","author":"Zhang","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.013_bib0026","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40291-025-00786-6","article-title":"Nectin-4-targeting radiotracers: novel theranostic agents for precision oncology in cancer","volume":"29","author":"Speltri","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett"},{"issue":"20","key":"10.1053\/j.semnuclmed.2025.11.013_bib0028","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.013_bib0029","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-025-04164-9","article-title":"Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance","author":"Kobayashi","year":"2025","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0031","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.013_bib0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-Nectin 4: a promising tumor cells target. a systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"1-2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2023.2288140","article-title":"NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?","volume":"24","author":"Filippi","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.013_bib0034","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12149-025-02090-z","article-title":"Recent advances in theranostics and oncology PET: emerging radionuclides and targets","volume":"39","author":"Watabe","year":"2025","journal-title":"Ann Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.013_bib0035","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0036","article-title":"Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET\/CT","author":"Miederer","year":"2025","journal-title":"BJU Int"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.013_bib0037","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.5c00469","article-title":"ImmunoPET Imaging of nectin4 expression in gastric and bladder cancer using [(64)Cu]Cu-NOTA-Padcev","volume":"22","author":"Huang","year":"2025","journal-title":"Mol Pharm"},{"issue":"17","key":"10.1053\/j.semnuclmed.2025.11.013_bib0038","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-human study of the radioligand 68Ga-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.013_bib0039","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1016\/j.acra.2024.02.014","article-title":"The value of dual time point (18)F-FDG PET\/CT imaging in differentiating lymph node metastasis from reactive hyperplasia in bladder urothelial carcinoma","volume":"31","author":"Zhou","year":"2024","journal-title":"Acad Radiol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.013_bib0040","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2967\/jnumed.125.270132","article-title":"[(64)Cu]Cu-NOTA-EV-F(ab')(2) enables same-day immuno-PET imaging of nectin-4 in triple-negative breast and urothelial bladder cancers","volume":"66","author":"Huang","year":"2025","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.013_bib0041","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0042","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2025.09.003","article-title":"Nectin-4, bladder cancer, and nuclear medicine: a theranostic frontier","author":"Kabunda","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0043","series-title":"Seminars in Nuclear Medicine","article-title":"FAPI PET in the management of lung tumors","author":"Deleu","year":"2025"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.013_bib0044","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: a systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.013_bib0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.semnuclmed.2025.06.011","article-title":"The value of FAPI PET\/CT in cholangiocarcinoma and pancreatic cancer: an update","volume":"55","author":"Pabst","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0046","series-title":"Urologic Oncology: Seminars and Original Investigations","article-title":"Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: a multicenter cohort from the European Association of Urology\u2013Young Academic Urologists","author":"Lonati","year":"2022"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0047","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00259-022-05761-5","article-title":"Feasibility of [68Ga] Ga-FAPI-46 PET\/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma","volume":"49","author":"Unterrainer","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0048","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bju.12447","article-title":"Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone","volume":"114","author":"Mertens","year":"2014","journal-title":"BJU Int"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0049","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2967\/jnumed.123.266390","article-title":"Initial experience with 68Ga-FAP-2286 PET imaging in patients with urothelial cancer","volume":"65","author":"Koshkin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.humpath.2019.07.002","article-title":"The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5\/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder","volume":"91","author":"Calvete","year":"2019","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.013_bib0051","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2025.11.013_bib0052","first-page":"1","article-title":"68Ga-FAPI and 18F-FAPI PET\/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients","author":"Unterrainer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.013_bib0053","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s00259-024-06595-z","article-title":"68 Ga] Ga-FAPI-46 PET\/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis","volume":"51","author":"Unterrainer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0054","first-page":"5","article-title":"Fibroblast activation protein identifies progressive bladder cancer and allows peritoneal metastasis detection by 68Ga-FAPI PET\/CT imaging. Europe PMC website","volume":"8","author":"Viergever","year":"2024","journal-title":"J Med Imaging Case Rep"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0055","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/cancers17020232","article-title":"Nuclear medicine and molecular imaging in urothelial cancer: current status and future directions","volume":"17","author":"McDonald","year":"2025","journal-title":"Cancers"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0056","article-title":"FAPI-PET\/CT findings in patients with urothelial carcinoma treated with enfortumab-vedotin and pembrolizumab vs. standard platinum-based chemotherapy","volume":"66","author":"Assadi","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0057","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010212","article-title":"FAP-targeted radioligand therapy with 68Ga\/177Lu-DOTA-2P (FAPI) 2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J ImmunoTher Cancer"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.013_bib0058","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"19","key":"10.1053\/j.semnuclmed.2025.11.013_bib0059","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.013_bib0060","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.semnuclmed.2025.06.010","article-title":"[177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review","volume":"55","author":"Al-Ibraheem","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0061","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11307-011-0488-0","article-title":"Initial results with (11)C-acetate positron emission tomography\/computed tomography (PET\/CT) in the staging of urinary bladder cancer","volume":"14","author":"Sch\u00f6der","year":"2012","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.013_bib0062","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1016\/j.ejrad.2012.06.010","article-title":"Prospective evaluation of MRI, 11C-acetate PET\/CT and contrast-enhanced CT for staging of bladder cancer","volume":"81","author":"Vargas","year":"2012","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0063","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40644-018-0158-4","article-title":"(11)C-acetate PET\/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)","volume":"18","author":"Salminen","year":"2018","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.013_bib0064","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-017-2168-4","article-title":"Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Kim","year":"2018","journal-title":"World J Urol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0065","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00259-002-0881-7","article-title":"Visualisation of bladder cancer using (11)C-choline PET: first clinical experience","volume":"29","author":"de Jong","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.013_bib0066","first-page":"938","article-title":"Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings","volume":"47","author":"Picchio","year":"2006","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0067","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/RLU.0000000000000604","article-title":"11C-choline PET\/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard","volume":"40","author":"Ceci","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"50","key":"10.1053\/j.semnuclmed.2025.11.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013344","article-title":"Direct comparison of choline PET\/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0069","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.juro.2011.03.121","article-title":"Comparison of 11C-choline with 18F-FDG in positron emission tomography\/computerized tomography for staging urothelial carcinoma: a prospective study","volume":"186","author":"Golan","year":"2011","journal-title":"J Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0070","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000000573","article-title":"11C-choline PET\/CT for restaging of bladder cancer","volume":"40","author":"Graziani","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0071","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000357686","article-title":"Prognostic value of 11C-choline PET\/CT and CT for predicting survival of bladder cancer patients treated with radical cystectomy","volume":"93","author":"Maurer","year":"2014","journal-title":"Urol Int"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.013_bib0072","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/RLU.0000000000001754","article-title":"Incidental papillary bladder carcinoma on 18F-fluoromethylcholine PET\/CT undertaken to evaluate prostate malignancy","volume":"42","author":"Parekh","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0073","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2967\/jnmt.119.230581","article-title":"Characterizing and mitigating bladder radioactivity on (18)F-fluciclovine PET\/CT","volume":"48","author":"Lovrec","year":"2020","journal-title":"J Nucl Med Technol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.013_bib0074","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1007\/s00259-025-07287-y","article-title":"A pilot study of [(18)F]F-fluciclovine positron emission tomography\/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy","volume":"52","author":"Ng","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0075","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1097\/RLU.0000000000003342","article-title":"Incidental detection of urothelial carcinoma on 18F-fluciclovine PET\/CT","volume":"46","author":"Surasi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.013_bib0076","first-page":"713","article-title":"Detection of additional primary neoplasms on (18)F-fluciclovine PET\/CT in patients with primary prostate cancer","volume":"63","author":"Parihar","year":"2022","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.013_bib0077","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/02841859609173441","article-title":"Positron emission tomography in the diagnosis and staging of urinary bladder cancer","volume":"37","author":"Ahlstr\u00f6m","year":"1996","journal-title":"Acta Radiol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.013_bib0078","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.21873\/anticanres.17216","article-title":"[(11)C]Methionine PET vs. [(18)F]fluorodeoxyglucose PET whole-body imaging to determine the extent of methionine-addiction compared to glucose-addiction of primary and metastatic cancer of the trunk in patients","volume":"44","author":"Sato","year":"2024","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.013_bib0079","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/ijms24031935","article-title":"Superiority of [(11)C]methionine over [(18)F]deoxyglucose for PET imaging of multiple cancer types due to the methionine addiction of cancer","volume":"24","author":"Kubota","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.013_bib0080","first-page":"234","article-title":"(11)C-Methionine uptake in secondary brain epilepsy","volume":"33","author":"Lopci","year":"2014","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0081","doi-asserted-by":"crossref","first-page":"9777","DOI":"10.1038\/s41598-021-89160-0","article-title":"Spotlight on PSMA as a new theranostic biomarker for bladder cancer","volume":"11","author":"Tumedei","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.013_bib0082","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.euf.2021.07.016","article-title":"Urothelial carcinoma and prostate-specific membrane antigen: cellular, imaging, and prognostic implications","volume":"8","author":"Tariq","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0083","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/RLU.0000000000002720","article-title":"68Ga-PSMA PET\/CT uptake in the ureter caused by ligand expression in urothelial cancer","volume":"45","author":"Zacho","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.013_bib0084","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12149-017-1216-x","article-title":"Low levels of PSMA expression limit the utility of (18)F-DCFPyL PET\/CT for imaging urothelial carcinoma","volume":"32","author":"Campbell","year":"2018","journal-title":"Ann Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.013_bib0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/RLU.0000000000004246","article-title":"Prostate-specific membrane antigen-avid bone metastases from urothelial carcinoma of the bladder","volume":"47","author":"Zhao","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:49:04Z","timestamp":1773845344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0001299825001655"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.013","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of non-FDG agents in PET imaging of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}